Evidence map›Paper›PMID 41190074›Full record

ReviewFrontiers in immunology2025

Harnessing big data for precision medicine: radiomics based application of nanomaterials in MRI enhancement and multimodal therapy of hepatocellular carcinoma.

Hongbin Shen, Deshui Ran, Jida Zhu, Aoxiao Tao, Kai Zheng, Qing Zhu, Haijun Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hongbin Shen *College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Deshui Ran *Department of Imaging, Jinan Second People's Hospital, Jinan, China.
Jida ZhuDepartment of Imaging, Jinan Second People's Hospital, Jinan, China.
Aoxiao TaoSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Kai ZhengDepartment of Imaging Center, Jinan Nanshan People's Hospital, Jinan, China.
Qing ZhuDepartment of Imaging Center, Jinan Nanshan People's Hospital, Jinan, China.
Haijun WangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) ranks among the most lethal malignancies worldwide, characterized by its high metastatic potential and poor prognosis. Early and precise detection and diagnosis of HCC remain a major clinical challenge. Magnetic resonance imaging (MRI), as the most widely used noninvasive technique for diagnosing liver diseases, currently suffers from limitations in traditional contrast agents, including low specificity and limited sensitivity, particularly when detecting small lesions. The emergence of nanotechnology offers novel approaches to enhance the diagnostic accuracy and therapeutic efficacy for HCC. Under the framework of big data driven precision medicine, this study explores the application of nanomaterials in HCC MRI enhancement and multimodal therapy. This review comprehensively summarizes two types of responsive nanomaterials: (1) Chiral Ni(OH)

Indexed as

Big DataCarcinoma, HepatocellularLiver NeoplasmsMagnetic Resonance ImagingNanostructuresPrecision MedicineAnimalsCombined Modality TherapyContrast MediaHumansRadiomicsContrast MediaAI driven radiomicshepatocellular carcinomaMRI enhancementmultimodal therapynanomaterials

Identifiers

PMID41190074
PMCPMC12580344

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.